Le Lézard
Classified in: Health
Subject: SVY

The human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023


NEW YORK, Feb. 11, 2019 /PRNewswire/ -- About this market
Technological advances in diagnostics to drive market growth. The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test. Pap test is a screening procedure for cervical cancer, in which the presence of precancerous or cancerous cells is identified on the cervix. Colposcopy is a more advanced technique like a Pap test, which allows the examiner to take abnormal cell tissues from the cervix. Technavio's analysts have predicted that the human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023.

Read the full report: https://www.reportlinker.com/p05734222

Market Overview
Advent of vaccines
The global HPV therapeutics market witnessed strong advances in terms of prevention of diseases caused by HPV. This is primarily due to the increasing research on developing highly advanced vaccines with a longer half-life. Vaccines were proved to have strong efficacy toward the prevention of various disease-causing viruses and highly effective toward the prevention of various indications caused by HPV.
Multiple-dose schedules of vaccines
Despite the availability of vaccines for the prevention of indications caused by HPV, the market faces a challenge from their recurring doses. As the vaccines that are currently approved for HPV are developed for administering through invasive methods such as subcutaneous route, the need for multiple doses affects the patient adherence toward the completion of the dose cycle.
For the detailed list of factors that will drive and challenge the growth of the human papillomavirus (HPV) therapeutics market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be fragmented and with the presence of several companies including ALLERGAN and Bausch Health the competitive environment is quite intense. Factors such as the advent of vaccines and the technological advances in diagnostics, will provide considerable growth opportunities to human papillomavirus (HPV) manufactures. ALLERGAN, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings, and Merck Sharp & Dohme are some of the major companies covered in this report.

Read the full report: https://www.reportlinker.com/p05734222

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 17:05
Illinois developmental disability providers can submit Therap generated ROCS Fee-for-Service claim files (Report) directly into DHS. The ROCS Billing option allows providers to download ROCS' Fee-for-Service Claim Files and import this FFS Claims...

at 17:03
Therap's web-based disability software for providers supporting individuals with intellectual and developmental disabilities now features additional options for documenting Electronic Visit Verification (EVV) services.  With the offline option...

at 17:01
Therap Global announces its upcoming information session to be held March 28, 2019 in Kathmandu, Nepal. The full day information session offers an opportunity for those working in the Nepalese disability community to come together and discuss...

at 17:00
Dr. Srini Pillay is a Harvard psychiatrist, former brain researcher and author of "Tinker Dabble Doodle Try: Unlock the Power of the Unfocused Mind." He is also an entrepreneur and an assistant professor at Harvard University, where he has spent a...

at 17:00
Liberty Health Sciences Inc. www.libertyhealthsciences.com ("Liberty" or the "Company"), as mentioned in the Company's Feb 12, 2019 press release, continues to work towards enhancing its directors and senior executives based in the United States,...

at 17:00
Verge Health, the healthcare industry's leading governance, risk, and compliance (GRC) company, has been exclusively endorsed by the Texas Hospital Association as a partner to help Texas hospitals more efficiently and effectively manage risk to...



News published on 11 february 2019 at 20:05 and distributed by: